Research map: Why the minimum effective dose is unidentifiable – and how a DOR→OOD standard delivers label-ready dosing in oncology

Back to the article

Papers in this map

  1. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer · Tony S.K. Mok · 2016 · 3397 citations · Cited by this paper
  2. Statistical approaches to classify investigational product using hERG safety assay · 2026 · Related
  3. AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer · Pasi Antero Janne · 2015 · 2139 citations · Cited by this paper
  4. Advances in statistical methodologies for assessing bioequivalence of topical dermatological products · 2026 · Related
  5. Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer · John O’Quigley · 1990 · 1590 citations · Cited by this paper
  6. Real-world data and evidence in the development of cell and gene therapies · 2026 · Related
  7. Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component · James Chih‐Hsin Yang · 2017 · 581 citations · Cited by this paper
  8. Robust CATE estimation using novel ensemble methods · 2026 · Related
  9. Critical aspects of the Bayesian approach to phase I cancer trials · Beat E. Neuenschwander · 2008 · 444 citations · Cited by this paper
  10. Augmented match weighted estimators: new methods for estimating average treatment effects under extreme propensity scores · 2026 · Related
  11. Population pharmacokinetics and exposure‐response of osimertinib in patients with non‐small cell lung cancer · Kathryn H. Brown · 2016 · 151 citations · Cited by this paper
  12. Sample sizes for randomized controlled trials utilizing Bayesian response adaptive randomization for continuous outcomes · 2026 · Related
  13. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials · Ruitao Lin · 2017 · 74 citations · Cited by this paper
  14. Non-inferiority testing for the odds ratio in two independent binomial proportions using the method of variance estimates recovery · 2026 · Related
  15. Evaluating biomarkers for prognostic enrichment of clinical trials · Kathleen F. Kerr · 2017 · 39 citations · Cited by this paper
  16. Bayesian quantitative decision-making framework in cell and gene therapy development for rare diseases · 2026 · Related
  17. BF ‐ BOIN ‐ ET : A Backfill Bayesian Optimal Interval Design Using Efficacy and Toxicity Outcomes for Dose Optimization · Kentaro Takeda · 2025 · 8 citations · Cited by this paper
  18. Analyze paired case–control data prospectively in comparing two predictive values · 2026 · Related
  19. Totality of the Evidence: Optimizing Dosage Selection Strategies in Oncology · Laura A. Levit · 2025 · 7 citations · Cited by this paper
  20. Parallelism of four-parameter logistic bioassay models: equivalence testing for parameter differences* · 2026 · Related

Source: OpenAlex (CC0)